<span item_type="fundamental" item_id="ae39bdd6a6a90cf9e0dee55149d4f414" counter_id="ST/US/TXMD" env="prod"></span><span item_type="announcement" item_id="582283275776953985" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 784 K.</p><p>EPS: As of FY2025 Q3, the actual value is USD 0.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -862 K.</p><p></p><h3>Net Income (Loss) from Continuing Operations</h3><ul><li>Net income from continuing operations was $50 thousand, or $0.00 per basic and diluted common share, compared to a net loss of $567 thousand, or $0.05 per basic and diluted common share, for the third quarter of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/25743/000121390025109479/ea026541601ex99-1_therape.htm"></span></li></ul><h3>License Revenues from Continuing Operations</h3><ul><li>License revenue, primarily from the Mayne License Agreement, totaled $784 thousand for the third quarter of 2025, an increase of $237 thousand compared to $547 thousand in license revenue for the third quarter of 2024. The increase is attributable to changes in sales of licensed products.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/25743/000121390025109479/ea026541601ex99-1_therape.htm"></span></li></ul><h3>Total Operating Expenses from Continuing Operations</h3><ul><li>Total operating expenses for the third quarter of 2025 were $1,646 thousand, a decrease of $35 thousand, or 2.1%, compared to the third quarter of 2024, reflecting minimal change from the third quarter of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/25743/000121390025109479/ea026541601ex99-1_therape.htm"></span></li></ul><h3>Balance Sheet</h3><ul><li>As of September 30, 2025, the Company’s cash and cash equivalents totaled $7.1 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/25743/000121390025109479/ea026541601ex99-1_therape.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>The Company continues to evaluate a variety of strategic alternatives that may include an acquisition, merger, other business combination, sale of assets, or other strategic transactions. There is no assurance of a transaction or successful outcome, and the Company has not set a timetable for completion of this exploration process.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/25743/000121390025109479/ea026541601ex99-1_therape.htm"></span></li></ul>

Therapeutics MD | 8-K: FY2025 Q3 Revenue: USD 784 K